Reduction of affective lability and alcohol use following traumatic brain injury: A clinical pilot study of anti-convulsant medications

Brain Injury

Volumn 19, Issue 4, 2005, Pages 309-313

  Beresford, Thomas P ^a,b   Arciniegas, David ^c,d   Clapp, Lori ^b   Martin, Brandon ^b   Alfers, Julie ^b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^d HealthONE Spalding Rehabilitation Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; MOOD STABILIZER; VALPROATE SEMISODIUM;

ADULT; ALCOHOL ABSTINENCE; ALCOHOL CONSUMPTION; ALCOHOLISM; ANXIETY DISORDER; ARTICLE; BRAIN INJURY; CLINICAL ARTICLE; CLINICAL STUDY; CONTROLLED STUDY; DATA ANALYSIS; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRINKING BEHAVIOR; EMOTIONAL DISORDER; FEMALE; HEALTH PROGRAM; HUMAN; MALE; MEDICAL RECORD; MENTAL INSTABILITY; OUTPATIENT DEPARTMENT; PILOT STUDY; RETROSPECTIVE STUDY; SELF MEDICATION; SUBSTANCE ABUSE; SYMPTOMATOLOGY; TREATMENT INDICATION; TREATMENT OUTCOME;

EID: 13844307778     PISSN: 02699052     EISSN: None     Source Type: Journal    
DOI: 10.1080/02699050410001720121     Document Type: Article

References (21)

1. Miller N. Alcohol and drug disorders. In: Silver JM, Yudofsky SC, Hales RE, editors. Neuropsychiatry of Traumatic Brain Injury. Washington DC: American Psychiatrc Press Inc.; 1994; pp 471-512.
2. Hibbard MR, Uysal S, Kepler K, et al. Axis I psychopathology in individuals with traumatic brain injury. Journal of Head Trauma Rehabilitation 1998;13:24-39.
3. Bourdon KH, Rae DS, Locke BZ, et al. Estimating the prevalence of mental disorders in US adults from the Epidemiologic Catchment Area Survey. Public Health Reports 1992;107:663-8.
4. Schneider U, Altmann A, Baumann M, et al. Comorbid anxiety and affective disorder in alcohol-dependent patients seeking treatment: The first Multicentre Study in Germany. Alcohol & Alcoholism 2001;36:219-23.
5. Longo LP, Campbell T, Hubatch S. Divalproex sodium (Depakote) for alcohol withdrawal and relapse prevention. Journal of Addictive Diseases 2002;21:55-64.
6. Brady KT, Myrick H, Henderson S, et al. The use of divalproex in alcohol relapse prevention: A pilot study. Drug & Alcohol Dependence 2002;67:323-30.
7. Johnson BA, Ait-Daoid N, Bowden CL, et al. Oral topiramate for treatment of alcohol dependence: A randomised controlled trial. [comment]. Lancet 2003;361:1677-85.
8. Arciniegas DB, Topkoff J. The neuropsychiatry of pathologic affect: An approach to evaluation and treatment. Seminars in Clinical Neuropsychiatry 2000;5:290-306.
9. Koponen S, Taiminen T, Portin R, et al. Axis I and II psychiatric disorders after traumatic brain injury: A 30-year follow-up study. American Journal of Psychiatry 2002;159:1315-21.
10. Palmer A, Marion D, Botscheller M, et al. Increased transmitter amino acid concentration in human ventricular CSF after brain trauma. Neuroreport 1994;6:153-6.
11. O'Dell DM, Hamm RJ. Chronic post-injury administration of MDL 26,479 (Suritozole), a negative modulator at the GABAA receptor, and cognitive impairment in rats following traumatic brain injury. Journal of Neurosurgery 1995; 83:878-83.
12. Reeves TM, Lyeth BG, Phillips LL, et al. The effects of traumatic brain injury on inhibition in the hippocampus and dentate gyrus. Brain Research 1997;757:119-32.
13. Erb DE, Povlishock JT. Neuroplasticity following traumatic brain injury: A study of GABAergic terminal loss and recovery in the cat dorsal lateral vestibular nucleus. Experimental Brain Research 1991;83:253-67.
14. Petty F. GABA and mood disorders: A brief review and hypothesis. Journal of Affective Disorders 1995;34:275-81.
15. Oruc L, Verheyen GR, Furac I, et al. Positive association between the GABRA5 gene and unipolar recurrent major depression. Neuropsychobiology 1997;36:62-4.
16. Papadimitriou GN, Dikeos DG, Karadima G, et al. Association between the GABA(A) receptor alpha5 subunit gene locus (GABRA5) and bipolar affective disorder. American Journal of Medical Genetics 1998;81:73-80.
17. Perucca E. Pharmacological and therapeutic properties of valproate: A summary after 35 years of clinical experience. CNS Drugs 2002;16:695-714.
18. White HS. Comparative anticonvulsant and mechanistic profile of the established and newer antiepileptic drugs. Epilepsia 1999;40 (Suppl 5):S2-10.
19. Kawata Y, Okada M, Murakami T, et al. Pharmacological discrimination between effects of carbamazepine on hippocampal basal, Ca(2+)- and K(+)-evoked serotonin release. British Journal of Pharmacology 2001;133:557-67.
20. Ichikawa J, Meltzer HY. Valproate and carbamazepine increase prefrontal dopamine release by 5-HT1A receptor activation. European Journal of Pharmacology 1999; 380:R1-3.
21. Corrigan JD. Substance abuse as a mediating factor in outcome from traumatic brain injury. Archives of Physical Medicine & Rehabilitation 1995;76:302-9.